SUBCUTANEOUS INJECTIONS OF CABOTEGRAVIR▼ + RILPIVIRINE▼ IN VIRALLY SUPPRESSED ADULTS WITH HIV-1: A SUBSTUDY OF THE PHASE 3 FLAIR STUDY

This page intends to provide information presented at recent congresses relevant to your unsolicited enquiry. Regulations vary by country, and some information may be off label (not authorised) in your country. Please refer to local product information before prescribing. ViiV Healthcare do not advocate off -label use of their medicines.

Start new search

NP-GBL-HVX-WCNT-240015 June 2024

Report an adverse event

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221441.

If you are from outside the UK, you can report adverse events to GSK/ViiV by selecting your region and market, here.

ViiV Healthcare
GSK HQ
79 New Oxford Street
London
WC1A 1DG
United Kingdom

Tel. +44 (0)20 8380 6200

ViiV Healthcare

NP-GBL-HVX-WCNT-220005 August 2023

This is a medical information resource for healthcare professionals only. Information provided within this side has been approved to UK regulations and may be subject to different medical and regulatory requirements in other countries. It is important to follow local laws and regulations when prescribing medicines.